UNSPSC 51141593: Fosphenytoin sodium

This classification denotes an anticonvulsant agent with the molecular formula C16H13N2O6P.2Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7VLR55452Z, chemically known as 2,4-imidazolidinedione, 5,5-diphenyl-3-((phosphonooxy)methyl)-, disodium salt but more generally known as fosphenytoin sodium, which bears US NIH Compound Identifier 56338. European Medicines Agency schedules Fosphenytoin sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13919MIG.

UNSPSC 51141593 Fosphenytoin sodium (Commodity) encompasses pharmaceutical products—primarily anticonvulsant medications and emergency therapeutic agents—that state and local governments procure for public health, emergency medical services, and community health programs. Recent solicitations show demand extending beyond the code's nominal scope to include broader categories of pharmaceuticals, naloxone, and OTC products distributed through public health agencies, county health departments, and cooperative purchasing alliances serving multiple jurisdictions. State and local buyers under this code span county health departments, state HHS commissions, and regional cooperative purchasing organizations. Seminole County, Florida, and the Texas Health and Human Services Commission represent the primary issuing bodies in recent activity, with the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) managing multi-state procurement coordinating purchases across participating state and local facilities including Oregon. Issuing bodies typically require vendors to meet cGMP and Drug Supply Chain Security Act compliance, maintain approved wholesaler relationships, provide detailed NDC and product information, and demonstrate insurance coverage including commercial general liability ranging up to $5 million per occurrence.

Recent activity clusters in Florida, Texas, and Minnesota. Representative opportunities include Seminole County's IFB60459723LAS, posted June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a July 26, 2023 response deadline; Texas HHS Commission's RFI HHS0017013, posted April 3, 2026, to gather vendor capabilities for a direct-to-manufacturer prescription program; and MMCAP's S1070000015802, posted January 20, 2026, establishing multiple-award contracts for generic pharmaceuticals and OTC products with a March 26, 2026 deadline and July 1, 2026 effective date. The MMCAP procurement emphasizes price competitiveness (75 percent weight), compliance with administrative data format requirements, EDI capability, and fixed pricing structures, with two-year contract terms and optional extensions. Vendors should expect 3 percent administrative fees and performance penalties for late reporting or missed onboarding timelines.